Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Celexa
Synonyms :
Class :
Selective serotonin reuptake inhibitors and Antidepressants
Brand Name :
Celexa
Synonyms :
Class :
Selective serotonin reuptake inhibitors and Antidepressants
Dosage Forms & Strengths Â
Tablet  Â
10mg Â
20mg Â
40mg Â
Oral-solution Â
10mg/5mL Â
Dosage Forms & Strengths Â
Tablet  Â
10mg Â
20mg Â
40mg Â
Oral-solution Â
10mg/5mL Â
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may have an increased antiplatelet effect when combined with NSAIDs
when both drugs are combined, there may be increased toxicity of citalopram by QTC interval  
may increase the serum concentration of colchicine
may enhance the serum concentrations of active metabolites
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the tachycardic effect of Alpha-/Beta-Agonists
may diminish the serum concentration of Voxelotor
omeprazole: they may enhance the serum concentration of citalopram
acetaminophen/doxylamine/dextromethorphanÂ
may increase the serotonergic effect when combined
lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors
sirolimus: they may enhance the serum concentration of CYP3A4 Inhibitors
may have an increased QTc-prolonging effect when combined with citalopram
budesonide: they may enhance the serum concentration of CYP3A4 Inhibitors
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
alfentanil: they may enhance the serum concentration of CYP3A Inhibitors
budesonide: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cisapride: they may enhance the serum concentration of CYP3A Inhibitors
dapoxetine: they may enhance the serum concentration of CYP3A Inhibitors
eliglustat: they may enhance the serum concentration of CYP3A Inhibitors
fentanyl: they may enhance the serum concentration of CYP3A Inhibitors
lumateperone: they may enhance the serum concentration of CYP3A Inhibitors
mitapivat: they may enhance the serum concentration of CYP3A Inhibitors
naloxegol: they may enhance the serum concentration of CYP3A Inhibitors
omaveloxolone: they may enhance the serum concentration of CYP3A Inhibitors
pexidartinib: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
suvorexant: they may enhance the serum concentration of CYP3A Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
may have an increasingly adverse effect when combined with selective serotonin reuptake inhibitors
aclidinium: they may enhance the serum concentration of CYP3A Inhibitors
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
It may enhance the toxicity when combined with sufentanil by serotonin levels
It may enhance QTc interval when combined with lithium
May increase the hypoglycemic effect of each other when combined
the QTc-prolonging effect of citalopram can be increased with QT-prolonging agents
the QTc-prolonging effect of citalopram can be increased with QT-prolonging agents
the QTc-prolonging effect of citalopram can be increased with QT-prolonging agents
the QTc-prolonging effect of citalopram can be increased with QT-prolonging agents
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
when both drugs are combined, there may be an increased risk or severity of QTC prolongation  
when both drugs are combined, both increase the QTC interval   
CYP3A strong enhancers of the small intestine may reduce the bioavailability of citalopram
when used together, entrectinib and citalopram both increase the QTc interval
when used together, encorafenib and citalopram both increase the QTc interval
when both drugs are combined, there may be an increase in the QTC interval
it increases the antiplatelet impact of escitalopram
may increase the QTc interval when combined
may enhance the serum concentration
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
they decrease the concentration of lurbinectedin in the serum
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
pimozide: they may enhance the serum concentration of CYP3A4 Inhibitors
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
may have an increased risk of hypoglycemia when combined with citalopram
fexinidazole: they may enhance the serum concentration of CYP3A4 inhibitors
fusidic acid: they may enhance the serum concentration of CYP3A inhibitors
trabectedin: they may diminish the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
elacestrant: they may enhance the serum concentration of CYP3A Inhibitors
fosaprepitant: they may enhance the serum concentration of CYP3A Inhibitors
infigratinib: they may diminish serum concentrations of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
methysergide: they may enhance the serum concentration of CYP3A Inhibitors
simeprevir: they may enhance the serum concentration of CYP3A Inhibitors
may have an increased serotonergic effect when combined with selective serotonin reuptake inhibitors
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
benzthiazide: it may increase the risk of adverse effects with CYP3A inhibitors
betaine: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
dactinomycin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the serum concentration
may increase the serum concentration
bazedoxifene/conjugated estrogens
may increase the serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
it may enhance the risk of QTc prolongation when combined with amifampridine
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
when ajmaline is used together with citalopram, the risk or seriousness of QTc prolongation is enhanced
Combining tegafur with citalopram can reduce tegafur’s metabolism
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
When alprazolam and citalopram is used together, this leads to reduction in the alprazolam’s metabolism
When dexrabeprazole and citalopram is used together, this leads to reduction in the dexrabeprazole’s metabolism
When ponesimod is used together with citalopram, this leads to enhanced risk or seriousness of bradycardia
When citalopram is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When citalopram is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
When citalopram is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When indisulam is used together with citalopram, this leads to a reduction in citalopram metabolism
citalopram: it may increase the risk of bleeding with trapidil
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
QTc interval is increased both by lenvatinib and citalopram
the effect of citalopram is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
it may increase the effect of other selective serotonin reuptake inhibitors
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
may increase the levels of each other by decreasing the metabolism
May enhance the effects of the other by pharmacodynamic synergism
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
they decrease the concentration of active metabolites of roflumilast in the serum
may increase the serum concentration
may increase the serum concentration of CYP3A4 substrates
azelastine/fluticasone intranasalÂ
may enhance the serum concentration
may increase the serum concentration of abemaciclib
may increase the hyponatremic effect of thiazide and thiazide-like diuretics
CYP3A4 inhibitors increase the concentration of carbamazepine in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
CYP3A4 inhibitors increase the concentration of rivaroxaban
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the serotonergic effect of Serotonin 5-HT1D Receptor Agonists
may increase the serotonergic effect of Serotonin 5-HT1D Receptor Agonists
may increase the serum concentration of Lidocaine
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may increase the levels of serum concentration of pimavanserin
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
It may enhance the serum concentration when combined with CYP3A4 Inhibitors
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may enhance the serum concentration of Vitamin D Analogs
SSRIs increase the CNS depressing effect of brexanolone
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
dofetilide: they may enhance the serum concentration of CYP3A Inhibitors
finerenone: they may enhance the serum concentration of CYP3A Inhibitors
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
fusidic acid and betamethasoneÂ
may enhance the serum concentration when combined
may enhance the risk of hypoglycemia when combined with Citalopram
may have an increased risk of gastrointestinal bleeding when combined with citalopram
clofazimine: they may enhance the serum concentration of CYP3A inhibitors
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alitretinoin: they may enhance the serum concentration of CYP3A Inhibitors
amiodarone: they may enhance the serum concentration of CYP3A Inhibitors
atorvastatin: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
barnidipine: they may enhance the serum concentration of CYP3A Inhibitors
bedaquiline: they may enhance serum concentrations of CYP3A Inhibitors
benidipine: they may enhance the serum concentration of CYP3A Inhibitors
buprenorphine: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
isavuconazonium sulfate: they may diminish serum concentrations of CYP3A Inhibitors
ebastine: they may enhance the serum concentration of CYP3A Inhibitors
felodipine: they may enhance the serum concentration of CYP3A inhibitors
gilteritinib: they may enhance the serum concentration of CYP3A inhibitors
macitentan: they may enhance the serum concentration of CYP3A Inhibitors
manidipine: they may enhance the serum concentration of CYP3A Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
It may enhance the risk of adverse effects when combined with calcium
When citalopram is aided by hesperetin, it reduces hesperetin’s metabolism
relebactam: it may decrease the excretion of CYP3A inhibitors
cabotegravir: it may decrease the excretion of CYP3A inhibitors
capmatinib: it may decrease the excretion of CYP3A inhibitors
cefaclor: it may decrease the excretion of CYP3A inhibitors
cefalotin: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
diclofenac: it may decrease the excretion of CYP3A inhibitors
dolutegravir: it may decrease the excretion of CYP3A inhibitors
emtricitabine: it may decrease the excretion of CYP3A inhibitors
it may decrease the excretion of CYP3A inhibitors
ketoprofen: it may decrease the excretion of CYP3A inhibitors
fluprednisolone: it may increase the risk of adverse effects with CYP3A inhibitors
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
it increases the antiplatelet effect of fluoxetine
they increase the concentration of glasdegib in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
Adverse drug reactions:  Â
Frequency Defined Â
>10% Â
Xerostomia  Â
Increased sweating Â
Dry mouth  Â
Nausea  Â
Somnolence  Â
Insomnia  Â
1-10% Â
Dyspepsia Â
Anorexia  Â
Abdominal pain  Â
Agitation  Â
Impotence Â
Ejaculation disorder Â
Rhinitis  Â
Upper respiratory infection Â
Sinusitis Â
Dysmenorrhea Â
Pregnancy warnings:    Â
AU TGA Pregnancy Category: C
US FDA Pregnancy Category: CÂ
Breastfeeding warnings: Â
crosses into breast milk- knownÂ
Pregnancy Categories:      Â
Patient Information Leaflet   Â
Generic Name: CitalopramÂ
Why do we use Citalopram?Â
Citalopram belongs to the class of Selective serotonin reuptake inhibitors which helps to treat obsessive-compulsive disorder, depression, Major Depressive Disorder, Panic Disorder, Post-traumatic stress disorder, Generalized Anxiety Disorder, and Premenstrual Dysphoric Disorder
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
